AIkido Pharma Secures Interest in Electric Truck Maker, Tevva Motors Ltd
AIkido Pharma Inc. (AIKI) announced its equity interest in Tevva Motors Ltd, an electric truck manufacturer. Tevva specializes in modular electrification systems for medium-duty vehicles, tapping into a $100 billion global delivery truck market. CEO Anthony Hayes emphasized the growing demand for cost-effective, zero-emission solutions, with Tevva's technology already in use by partners like UPS and Hitachi. AIkido sees potential for shareholder value through Tevva's upcoming public listing. The company continues to focus on drug development while exploring high-growth opportunities.
- Equity interest secured in Tevva Motors Ltd, a leading electric truck producer.
- Tevva operates in a $100 billion global delivery truck market.
- Strong partnerships with notable companies like Ryder, Hitachi, and UPS.
- Potential for monetization events as Tevva plans for a public listing.
- None.
NEW YORK, Sept. 28, 2021 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that the Company secured an equity interest in Tevva Motors Ltd, an electric truck producer with range extended vehicles on the road now.
Tevva Motors Ltd is a UK-based, leading developer of modular electrification systems for medium duty commercial vehicles. Using a system engineering approach, Tevva has developed world-class electric vehicle technology that adheres to the most rigorous of standards to ensure safety, reliability and durability. Tevva's core proprietary technologies – comprising battery pack and management system, control system, software, and optional range extender – are applicable to almost any current 7.5t – 14t truck and is supplied as a package to OEMs for integration with their vehicles.
Anthony Hayes, CEO of AIkido, noted, "From a commercial standpoint, delivery trucks are a
About AIkido Pharma Inc.
AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology Company with a diverse portfolio of small-molecule anti-cancer therapeutics. The Company's platform consists of patented technology from leading universities and researchers, and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and University of Maryland at Baltimore. Our diverse pipeline of therapeutics includes therapies for pancreatic cancer and prostate cancer. We are constantly seeking to grow our pipeline to treat unmet medical needs in oncology. The Company is also developing a broad-spectrum antiviral platform that may potentially inhibit replication of multiple viruses including Influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the SEC, not limited to Risk Factors relating to its business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.
Contact:
Investor Relations:
Hayden IR
Brett Maas, Managing Partner
Phone: (646) 536-7331
Email: brett@haydenir.com
www.haydenir.com
AIkido Pharma Inc.
Phone: 212-745-1373
Email: investorrelations@aikidopharma.com
www.aikidopharma.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/aikido-pharma-secures-interest-in-electric-truck-maker-tevva-motors-ltd-301386841.html
SOURCE AIkido Pharma Inc.
FAQ
What is the recent news about AIkido Pharma Inc. (AIKI)?
How does AIkido's investment in Tevva Motors Ltd impact shareholders?
What market is Tevva Motors Ltd operating in?
Who are some of Tevva's strategic partners?